Here are a couple of recent articles on NAFLD, which is a HUGE market that Leronlimab should be able to address...so let's get those NASH results published ASAP!

https://www.usnews.com/news/health-news/artic...eart-risks

https://www.insider.com/heart-disease-many-ad...isk-2022-4